Considerable losses and extended timelines for drug approval are keeping ProMetic Life Sciences (ProMetic Life Sciences Stock Quote, Chart, News … [Read more...] about ProMetic Life Sciences has price target slashed at Echelon
Life Sciences
Content brought to you by:
The Cantech Letter Life Sciences section is brought to you by Relay Medical Corp. (CSNX:RELA). Relay is in the business of commercializing innovative technologies, protected by issued and pending patents, in the medical diagnostics and research field with an emphasis on In Vitro Diagnostics (IVD) and Point of Care Testing (POCT). Click on the logo for more info...
GW Pharmaceuticals has a strong pipeline, AltaCorp says
Impressive Epidiolex sales led to sparkling results for GW Pharmaceuticals (GW Pharmaceuticals Stock Quote, News, Chart NASDAQ:GWPH) in its latest … [Read more...] about GW Pharmaceuticals has a strong pipeline, AltaCorp says
Acerus Pharmaceuticals has a 270 per cent upside, says Mackie Research
A supply shortage of the company’s nasal testosterone replacement therapy will impact sales estimates over the next two quarters but the end result is … [Read more...] about Acerus Pharmaceuticals has a 270 per cent upside, says Mackie Research
Khiron Life Sciences stock has a 209 per cent upside, says AltaCorp
In a coverage launch, Khiron Life Sciences (Khiron Life Sciences Stock Quote, News, Chart TSXV:KHRN) gets a “Speculative Buy” rating from AltaCorp … [Read more...] about Khiron Life Sciences stock has a 209 per cent upside, says AltaCorp
Echelon lowers price target on Cipher Pharma, maintains “Buy” rating
With the stock on a multi-year decline and the board looking at its "strategic options", Echelon Wealth Partners analyst Doug Loe has lowered his … [Read more...] about Echelon lowers price target on Cipher Pharma, maintains “Buy” rating
Acasti Pharma still has more upside, Echelon Wealth says
Does Acasti Pharma still have upside? Echelon Wealth Partners analyst Douglas Loe could be forgiven for picking up his ball and going home, seeing … [Read more...] about Acasti Pharma still has more upside, Echelon Wealth says
Correvio Pharma has tonnes of upside, says Mackie Research
Recent share price weakness makes for a buying opportunity on Correvio Pharma (Correvio Pharma News, Stock Quote, Chart TSX, NASDAQ:CORV), says Mackie … [Read more...] about Correvio Pharma has tonnes of upside, says Mackie Research
Bellus Health gets new $4.10 price target at Mackie Research Capital
Recent shifts in the competitive landscape have Mackie Research Capital analyst André Uddin raising his price target on Bellus Health (Bellus Health … [Read more...] about Bellus Health gets new $4.10 price target at Mackie Research Capital
Medexus is Canada’s best specialty pharma stock, Mackie Research says
Following the company's fourth quarter results, Mackie Research Capital analyst André Uddin is describing Medexus Pharmaceuticals (Medexus … [Read more...] about Medexus is Canada’s best specialty pharma stock, Mackie Research says
Sernova Corporation has an upside of 317 per cent, Echelon says
Impressive interim outcome data from Sernova Corporation (Sernova Corporation News, Stock Quote, Chart TSXV:SVA) has Echelon Wealth Partners analyst … [Read more...] about Sernova Corporation has an upside of 317 per cent, Echelon says